Gifthealth Launches Off-the-Shelf Solution for Most Favored Nation Pricing

Why It Matters

The rapid, scalable MFN solution gives manufacturers a cost‑effective way to prove drug value while removing financial barriers for patients, accelerating therapy initiation and adherence across the U.S. market.

Key Takeaways

• Gifthealth handles over 90% of US DTP volume.
• New off‑the‑shelf MFN solution deploys in 21 days.
• Supports 35,000 daily patients with 91% satisfaction.
• Cuts prescription abandonment by 50% versus national average.
• Integrates with all major EHRs, hubs, and CRMs.

Pulse Analysis

The pharmaceutical landscape is increasingly driven by value‑based contracts, and Most Favored Nation pricing has emerged as a cornerstone for manufacturers seeking price parity across payer channels. Gifthealth’s new off‑the‑shelf solution translates that concept into a patient‑centric model, allowing drug makers to extend MFN terms directly to consumers through digital DTP programs. By automating electronic benefit investigations (eBI) and verifications (eBV), the platform reduces administrative friction, enabling faster access to affordable therapies and aligning with the broader industry push toward transparency and cost containment.

Speed and integration are the twin pillars of Gifthealth’s offering. The platform can be operational within three weeks, a timeline that dwarfs traditional DTP rollouts that often span months. Seamless connectivity with leading electronic health record (EHR) systems, pharmacy hubs, and customer relationship management (CRM) tools ensures that providers, payers, and manufacturers share real‑time data. This rapid deployment not only shortens time‑to‑market for new drugs but also equips manufacturers with actionable insights on utilization patterns, adherence, and out‑of‑pocket costs, fostering more informed pricing negotiations.

For the broader health ecosystem, Gifthealth’s solution signals a shift toward digitally enabled, patient‑first financing models. The reported 91% satisfaction score and a 50% drop in prescription abandonment suggest that removing cost barriers can materially improve therapeutic outcomes. As insurers and providers grapple with rising drug spend, scalable DTP platforms that deliver MFN pricing may become a standard component of formulary strategy, driving both cost efficiency and better health results across the United States.